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Sleep disturbance is among the many consequences of ethanol abuse in both humans and rodents. Ethanol consumption can
reduce REM or paradoxical sleep (PS) in humans and rats, respectively. The first aim of this study was to develop an animal
model of ethanol-induced PS suppression. This model administered intragastrically (by gavage) to male Wistar rats (3 months
old, 200-250 g) 0.5 to 3.5 g/kg ethanol. The 3.5 g/kg dose of ethanol suppressed the PS stage compared with the vehicle group
(distilled water) during the first 2-h interval (0-2 h; 1.3 vs 10.2; P < 0.001). The second aim of this study was to investigate the
mechanisms by which ethanol suppresses PS. We examined the effects of cholinergic drug pretreatment. The cholinergic
system was chosen because of the involvement of cholinergic neurotransmitters in regulating the sleep-wake cycle. A second
set of animals was pretreated with 2.5, 5.0, and 10 mg/kg pilocarpine (cholinergic agonist) or atropine (cholinergic antagonist).
These drugs were administered 1 h prior to ethanol (3.5 g/kg) or vehicle. Treatment with atropine prior to vehicle or ethanol
produced a statistically significant decrease in PS, whereas pilocarpine had no effect on minutes of PS. Although the mechanism
by which ethanol induces PS suppression is not fully understood, these data suggest that the cholinergic system is not the only
system involved in this interaction.
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Introduction
Ethanol has been documented to impair sleep quality by
causing sleep disturbances such as snoring and insomnia
(1-3). Studies of ethanol administration and its relationship
to sleep in experimental animals have demonstrated changes
quite similar to those seen in humans. Acute ethanol admin-
istration has been shown to reduce sleep latency (4) and
increase the percentage of slow wave sleep (SWS; 5).
Indeed, SWS was increased at doses of 0.5 and 1.5 g/kg,
whereas paradoxical sleep (PS) was decreased during the
first 6 h after 1.5 g/kg (5). In addition to the significant
impairment in the duration of PS, ethanol has a dose-
dependent effect on the sleep of rats; as the administration
of this substance increases, the percentage of PS signifi-
cantly decreases (6,7). Based on the literature, the develop-
ment of an animal model of ethanol-induced PS suppression
is extremely important to better understand the neural mech-
anisms underlying the effects of ethanol on sleep. Further-
more, this animal model should provide a tool to better
understand the mechanism by which ethanol can selectively
impair this particular stage of sleep. Therefore, the first aim
of the present study was to introduce and validate an animal
model of ethanol-induced PS suppression.
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The consistent effects that ethanol has on PS can be
due to its interaction with several neurotransmitters in the
central nervous system that have the capacity to impair
attention, memory, and executive functions in addition to
sleep regulation. Moreover, PS may be mediated by the
effect that ethanol has on either the steady-state levels or
turnover rates of one or more neurotransmitters.
Several studies during the past three decades have
shown an important role in sleep modulation for monoam-
inergic and cholinergic neurons located in the pontine
brainstem. Moreover, acetylcholine is a well-known neuro-
transmitter involved in various fundamental central func-
tions such as synchronization of the circadian cycle and
sleep-waking control (8). There is considerable evidence
indicating that the final effector mechanism responsible for
PS generation resides in the pontine reticular formation
(9). Moreover, pharmacological and neuroanatomical stud-
ies indicate that the PS switch-on mechanism may be
mediated by the cholinergic system (10). For instance,
microinjections of cholinergic agonists into the medial pon-
tine reticular formation readily trigger PS, whereas injec-
tions just outside this zone are ineffective (11). A musca-
rinic agonist (pilocarpine) was shown to both enhance the
processes of cortical activation of waking and shorten the
latency of PS (12,13). Ethanol also inhibits acetylcholine
release and increases central acetylcholine levels in rat
cortical slices (14,15), thereby antagonizing the effects of
ethanol. In addition, atropine (a cholinergic antagonist) in
doses greater than 3 mg/kg prevents physostigmine an-
tagonism mediated by ethanol (13). Although many stud-
ies have suggested a reciprocal interaction between the
cholinergic system and the generation of PS, it remains
difficult to relate the theoretical framework of this model
and the pharmacological data with the fact that selective
lesions of either cholinergic or monoaminergic nuclei in the
brainstem have relatively limited effects on PS. Thus, the
second aim of this study was to investigate the possible
role of the cholinergic system in the generation of PS in our
model of ethanol-induced PS suppression.
In the present study, we describe an animal model of
ethanol-induced PS suppression and provide data related
to the cholinergic system and the generation of PS. Since
ethanol significantly decreases PS, we hypothesized that




Male Wistar rats were bred and raised in the animal
facility of the Department of Psychobiology, Universidade
Federal de São Paulo. The animals were housed in a
colony maintained at 22 ± 2°C with a 12:12-h light–dark
cycle (lights on at 7:00 am) and allowed free access to food
and water inside standard polypropylene cages (31 x 34 x
31 cm). Rats used in this study were maintained and
treated in accordance with the guidelines established by
the Ethical and Practical Principles of the Use of Labora-
tory Animals (16). All experimental procedures were ap-
proved by the Ethics Committee of the Universidade Fede-
ral de São Paulo (CEP #1070/04).
Surgical preparation
The rats received ketamine hydrochloride and diazepam
anesthesia (80 and 4.5 mg/kg of body weight, ip). To record
cortical electrocorticogram (ECoG) with a minimum of theta
activity, one pair of screw electrodes was placed through the
skull: 1 mm posterior to bregma, 3 mm right to the central
suture, and 1 mm anterior to lambda, 4 mm right to the
central suture. To ensure the best recording of theta activity,
two screw electrodes were placed in a more medial posterior
position: 3 mm anterior to bregma, 1 mm left to the central
suture, and 4 mm anterior to lambda, 1 mm left to the central
suture. Electromyogram (EMG) electrodes were implanted
in the neck muscles, soldered to a 6-pin socket, and covered
with dental acrylic cement. After surgery, the rats were
placed individually in round transparent plastic cages and
had a 14-day surgery recovery period of 10 days without the
recording cable followed by a 4-day adaptation period with
the polysomnography cable connected.
Electrocorticogram recording and parameters
The animals remained in their home cages inside a
Faraday chamber in a soundproof room throughout the
experiment. Food and water were provided ad libitum. The
recordings were performed on a Nihon Koden Co. (Japan)
model QP 223-A apparatus using three channels for each
animal: two for ECoG and one for neck muscle EMG. The
EcoG signals were amplified and filtered with a low pass at
0.1 s (1.6 Hz), and EMG activity was filtered with a low pass
at 0.03 s (5.3 Hz). The recording equipment was placed in
an adjacent room. Throughout the recording sessions, the
rats were observed through a one-way glass window. The
ECoG traces were scored manually and blindly for 30 s
epochs. The sleep stages of wakefulness, SWS, and PS
were identified and scored according to a combination of
ECoG, EMG, and behavioral criteria (17,18). Briefly, dur-
ing periods of wakefulness, rats were standing, grooming,
scratching, moving around the cage, drinking or eating, or
lying down with occasional movements and eyelids open
paying attention to the environment. The ECoG trace for
these behaviors shows low amplitude theta waves accom-
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panied by high-amplitude EMG activity. SWS episodes
were characterized by a typical immobile posture with
closed eyelids. The ECoG features were low-frequency,
high-amplitude delta waves with occasional periods of
spindles activity occurring at higher frequencies. The EMG
was characterized by a reduction in muscle tone. The
sleep posture during PS was similar to that in SWS, but the
head was fully relaxed and there were twitches of the ears,
whiskers, and distal limbs. Breathing was frequent and
irregular, and the ECoG trace displayed low amplitude and
high frequency with theta waves. The EMG showed an
absence of muscle activity except for occasional twitches.
The following sleep parameters were considered: sleep
efficiency (total sleep time during the recording time),
sleep latency (time lag between the onset of recording and
the first sleep period), sleep onset (time at which the
animal presented cortical synchronization during five con-
secutive scoring epochs), PS latency (time lag between
the first sleep period and the first episode of PS), SWS
(time of all periods of deep sleep throughout the record-
ing), and PS (duration of all periods of PS throughout the
recording period).
Animal model of ethanol-induced PS suppression
It is known that ethanol is metabolized relatively quickly
(19). Although we have recorded for 12 h after ethanol
administration, we speculate that changes in the sleep
architecture occur in the first hours of the ECoG recording
as ethanol is metabolized. To assess the effects of acute
intragastric ethanol administration on sleep in rats, we
performed the experiment at 7 am with ECoG data collec-
tion every hour for the first 4 h and every 2 h thereafter. To
provide more comprehensive figures, we elected to depict
7:00-13:00 h as 0-6 h, and 13:00-19:00 h as 6-12 h after
ethanol administration.
Relationship between cholinergic drugs in the animal
model of ethanol-induced PS suppression
The cholinergic drugs are related to the presence of the
PS stage. We designed this experiment to determine
whether a cholinergic drug can induce PS in this rat model
of ethanol-induced PS suppression. The cholinergic drugs
pilocarpine and atropine were administered subcutane-
ously 1 h prior to the administration of ethanol. The ECoG
recording was obtained throughout the same time as the
induction of the PS suppression by ethanol administration.
The recording sessions were performed for 12 h.
Experimental protocols
Experiment 1. Effect of acute ethanol administration on
sleep pattern. The animals were assigned to one of six
groups consisting of 8 to 12 animals each. The treatment
consisted of intragastric administration (gavage) of etha-
nol solution or vehicle. The ethanol solution was 50%
ethanol v/v. On the experimental day, each group received
one of the five doses of ethanol: 0.5, 1.0, 2.0, 3.0, 3.5 g/kg,
and one group received 2.0 mL distilled water. The sleep of
the animals was recorded during the 12-h light period
(7:00-19:00 h).
Experiment 2. Effects of cholinergic drugs on sleep in
rats with suppression of PS. Seventy-two rats were allo-
cated into agonist and antagonist groups receiving pilo-
carpine and atropine, respectively. On the experimental
day, each rat received one of three doses of pilocarpine or
atropine (2.5, 5.0, 10 mg/kg) subcutaneously 1 h prior to
the light period (6:00 am). After 1 h (7:00 am), rats were
given ethanol (3.5 g/kg) or distilled water (2.0 mL) and
were immediately submitted to ECoG recording. We elected
to use the dose of 3.5 g/kg ethanol that suppressed PS and
altered latency to PS (see Results).
Statistical analysis
Data are reported as the mean ± standard error of the
mean (SEM). Homogeneity of variance was assessed by
the Bartlett test and normal distribution of the data by the
Kolmogorov-Smirnov test. Factorial analysis of variance
(ANOVA) was used to assess the data of sleep and PS
latencies (pilocarpine and atropine). One-way and two-
way ANOVA was used to analyze ethanol data and three-
way ANOVA to analyze group differences (ethanol x ve-
hicle), cholinergic treatment (pilocarpine/atropine x doses),
recording periods after ethanol administration (0-6- and 6-
12-h intervals), and interaction among these three factors.
The Tukey post hoc test was used to compare values of
different times of sleep intervals between groups. When
the Bartlett test showed absence of homoscedasticity,
data were square root transformed. P < 0.05 was consid-
ered to be statistically significant.
Results
Effects of administration of ethanol on sleep pattern
Sleep and PS latency. Figure 1 shows the effects of
vehicle or ethanol on sleep and PS latencies. No signifi-
cant alteration was observed in sleep latency; however,
the 3.5 g/kg ethanol group did show a significant increase
in the PS latency compared with vehicle and 0.5 g/kg
ethanol groups (P < 0.01).
Total time of PS. Repeated measures ANOVA indicated
a significant effect of treatments [F(5,52) = 3.73; P < 0.006]
and recording periods [F(5,260) = 40.8; P < 0.001], but no
significant interaction between these two factors [F(25,260)
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Figure 1. Effects of acute administration of ethanol on sleep (A)
and paradoxical sleep latencies (B) determined by the time lag
between the onset of recording and the first sleep period. Data
are reported as means ± SEM for 8-11 rats per group. *P < 0.01
compared to vehicle group, and +P < 0.02 compared to 0.5 g/kg
ethanol group (one-way ANOVA followed by the Tukey test).
Figure 2. Effects of acute administration of ethanol on the dura-
tion of paradoxical sleep. A, Time after ethanol administration. B,
Dose of ethanol. Data are reported as means ± SEM for 8-11
rats/group. *P < 0.05 compared to vehicle group and 0-2 h (two-
way ANOVA followed by the Tukey test).
= 1; P = 0.46]. Thus, the results shown in Figure 2A are
related to the effects of acute ethanol administration on the
duration of paradoxical sleep. These results were independ-
ent of the dose used. The dose-response curve showed a
reduction in PS after the administration of 2.0 and 3.5 g/kg
ethanol compared with the vehicle group (P < 0.05; Figure
2B). Within the first 2 h after ethanol administration, time of
PS was reduced compared to all periods (P < 0.001; Figure
2A) and a rebound effect was observed in all groups during
the 6-12-h period after ethanol administration.
Sleep efficiency and total time of SWS. Significant
increases occurred in sleep efficiency and SWS [F(5,260)
= 15.7; P < 0.001 and F(25,260) = 5.8; P = 0.001] in the 6-
12-h period after ethanol administration compared with the
0-2-h period. No significant effect was observed after etha-
nol administration on the sleep efficiency and SWS [F(5,52)
= 0.37; P = 0.86 and F(5,52) = 1.2; P = 0.29] and interaction
[F(25,260) = 1.1; P = 0.31 and F(25,260) = 1.4; P = 0.11].
Effects of concomitant administration of ethanol-
pilocarpine on the sleep pattern
Sleep and PS latency. Treatment with the muscarinic
antagonist pilocarpine (5 and 10 mg/kg) induced a signifi-
cant increase in sleep latency compared to the saline and
2.5 mg/kg groups [F(3,60) = 17.9; P < 0.001; Figure 3].
Furthermore, a significant increase in PS latency was
observed in the rats that received ethanol (3.5 g/kg) and
vehicle group [F(1,60) = 16.1; P < 0.001].
Total time of PS. Three-way ANOVA showed a signifi-
cant effect of ethanol [F(1,58) = 11.1; P < 0.001], recording
period [F(1,58) = 114.6; P < 0.001], and interaction [F(1,58)
= 12.8; P < 0.001]. No difference was observed after
pilocarpine administration.
Effects of concomitant administration of ethanol-
atropine on the sleep pattern
Sleep latency and PS latency. No significant differ-
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Figure 3. Effects of pilocarpine administration on the duration of
paradoxical sleep suppressed by ethanol [saline or ethanol (N =
12 and 11); 2.5 mg/kg pilocarpine and saline or ethanol (N = 7
and 8); 5 mg/kg pilocarpine and saline or ethanol (N = 8 and 11);
10 mg/kg pilocarpine and saline or ethanol (N = 5 and 6)]. At 6:00
h, each animal was given the appropriate dose of pilocarpine.
One hour after injection, each animal was challenged with 3.5 g/
kg ethanol. Data are reported as means ± SEM. *P < 0.05
compared to ethanol group (three-way ANOVA followed by the
Tukey test).
Table 1. Effect of atropine on sleep, paradoxical sleep latencies and duration of
paradoxical sleep suppressed by ethanol.
Vehicle Ethanol Vehicle Ethanol
Sleep latency
Saline 24.6 ± 3.7 13.5 ± 2.6
Atropine (2.5 mg/kg) 29.9 ± 5.0 16.5 ± 2.8
Atropine (5 mg/kg) 31.9 ± 13.5 19.7 ± 7.6
Atropine (10 mg/kg) 25.3 ± 5.3 9.9 ± 1.8
Paradoxical sleep latency
Saline 40.3 ± 10.7 150.9 ± 36.5*
Atropine (2.5 mg/kg) 204.4 ± 29.6* 253.6 ± 39.7*
Atropine (5 mg/kg) 202.2 ± 6.9* 295.9 ± 39.9*
Atropine (10 mg/kg) 91.7 ± 14.1*+ 215.3 ± 43.1*
Paradoxical sleep 0-6-h period 6-12-h period
Saline 42.5 ± 3.3 16.4 ± 3.6* 57.4 ± 4.4 52.2 ± 5.5**
Atropine (2.5 mg/kg) 12.6 ± 3.5* 7.4 ± 2.3* 52.6 ± 5.5** 41.1 ± 5.8**
Atropine (5 mg/kg) 14.5 ± 2.7* 4.8 ± 1.9* 63.4 ± 5.7** 44.7 ± 4.0**
Atropine (10 mg/kg) 31.2 ± 3.3 12.2 ± 3.2* 60.3 ± 3.3** 60.7 ± 4.8**
Data are reported as mean ± SEM. At 6 h, each animal was given an appropriate dose
of atropine. One hour after injection, each animal was challenged with 3.5 g/kg ethanol.
Saline (N = 12) or ethanol (N = 11); 2.5 mg/kg atropine and saline or ethanol (N = 10); 5
mg/kg atropine and saline or ethanol (N = 8); 10 mg/kg atropine and saline or ethanol (N
= 9).
*P < 0.05 compared to saline-vehicle group; +P < 0.05 compared to 2.5 or 5 mg/kg
atropine and ethanol groups; **P < 0.05 compared to 6-12-h period (two-way ANOVA
for sleep and paradoxical sleep latencies and three-way ANOVA for paradoxical sleep
followed by the Tukey test).
ences were observed in sleep latency after
atropine administration. There was a sig-
nificant increase of PS latency in all treat-
ments compared with the vehicle group
(Table 1). Once again, PS latency was
significantly increased after ethanol admin-
istration [F(1,69) = 20.6; P < 0.001] and
although atropine treatment displayed a
similar increase compared with the ethanol
group, PS latency was lower in the 10 mg/
kg atropine group compared to the 2.5 and
5.0 mg/kg groups [F(3,69) = 16; P < 0.001].
There was no interaction between the etha-
nol and atropine treatments.
Total time of PS. Three-way ANOVA
showed that there was a difference in PS
time between drug, ethanol and recording
periods; this was concomitant to a signifi-
cant interaction among these factors
[F(3,69) = 3.7; P < 0.02; Table 1]. Total time
of PS was markedly reduced after ethanol
and/or atropine treatments (P < 0.001) as
all groups showed reduced PS in the 0-6-h
interval compared to the vehicle, except for
the 10 mg/kg atropine-vehicle group. A
rebound effect was observed in all groups
787
Braz J Med Biol Res 41(9) 2008
 Paradoxical sleep reduction induced by ethanol
www.bjournal.com.br
in the second interval (6-12 h).
Discussion
The results reported here demonstrated a significant
dose effect of ethanol-induced suppression of PS in rats. In
the first ECoG recording hour, the dose of 3.5 g/kg ethanol
suppressed PS in all (N = 11) rats tested. In addition, at all
quantities of ethanol tested, there was a significant in-
crease in PS in the 6th hour after ethanol administration.
The adoption of 2-h intervals between scoring periods in
this investigation clearly showed the longitudinal effect of
ethanol on sleep architecture in all sleep parameters in a
manner suggesting that these alterations occur differently
for each parameter. In order to investigate the contribution
of the cholinergic system, a muscarinic agonist (pilocarpine)
and an antagonist (atropine) were administered 1 h prior to
ethanol. There was a significant reduction of PS during the
first 6 recording hours with 2.5 and 5.0 mg/kg atropine, and
these significantly reduced PS. Pilocarpine, in turn, did not
statistically alter the sleep architecture as expected.
The effects of ethanol on sleep architecture have been
described in the literature for both humans and animal
experimental paradigms. Dose-dependent inhibition of PS
in humans after acute administration of 0.9 g/kg ethanol
was reported in healthy volunteers, whereas SWS re-
mained unaltered (1). This finding indicates that ethanol
specifically modifies PS. A decrease of PS with a possible
rebound during the second half of the night (20) is a
frequent sleep disturbance evaluated by various investiga-
tors. Since a dose-related reduction of PS following etha-
nol administration is a common observation in normal
nonalcoholic subjects, the effects observed in animals
appear to be similar to those in normal human subjects.
In rodents, acute ethanol has been shown to reduce
sleep latency (4), increase SWS (5), and decrease PS in a
dose-dependent manner (7). The reduction in PS did not
reach statistical significance in an acute oral administra-
tion protocol (21), nor did it result in statistical changes in
the time spent in sleep following intragastric infusion of a
low ethanol dose in alcohol-preferring and alcohol-
nonpreferring rats (22). The route of administration seems
to provide an additional variable in the sleep pattern.
Inhalation, parenteral, oral (gastric), or intracerebroven-
tricular administration causes distinct results (21,22), and
a wide dose range also makes the scenario more complex.
These observations further reinforce the concept that the
effects of ethanol on sleep parameters are dependent on
the susceptibility of ethanol-preferring strains and the nor-
mal vigilance state of the animal (21). Differences were
found when the drug was administered at different times in
the rat circadian cycle (21).
More studies are needed to better understand the
neurobiological mechanisms underlying the reduction or
abolishment in PS following acute ethanol exposure. We
speculate that these consistent effects may be mediated
by the effect that ethanol has on either the steady-state
levels or turnover rates of one or more neurotransmitters.
This substance interacts with several neurotransmitters
within the central nervous system, including γ-aminobu-
tyric acid (GABA), serotonin, catecholamines, and opiates
(23). Although many studies have demonstrated the ef-
fects of ethanol on the central cholinergic system, these
studies reveal some conflicting findings. The mechanism
responsible for ethanol-induced PS inhibition suggests
that acute doses of ethanol cause inhibitory effects on the
central cholinergic pathways (15,24-26). It has also been
suggested that cholinergic neurons are a primary target for
ethanol in the brain (27,28). Such conjecture could be due
to in vitro and in vivo observations of the reduction of
acetylcholine release (14,15,24-26,29), which results in a
decrease of cholinergic activity since cholinergic agonists
induce (30) and antagonists block (12,31) PS. Thus, etha-
nol could inhibit glutamatergic neurons, reducing acetyl-
choline concentrations. Recently, an increase of acetyl-
choline transmission by systemic ethanol acting on cholin-
ergic dendrites and cell bodies (32) showed that the neuro-
chemical consequences of ethanol still warrant additional
studies.
In the present study, administration of atropine (+ ve-
hicle) and atropine treatment prior to ethanol exposure
caused a reduction in PS compared with the vehicle group.
Pilocarpine, in turn, did not modify PS in the three doses
tested. The reasons for the absence of effects on PS by
pilocarpine may be attributed to the distinct modulation
effect of agonist vs antagonist upon ethanol suppression
of PS on the central nervous system. Much data have been
shown in the literature describing the effects of ethanol on
biological substrates. Clinical sleep studies are hampered
by a reduced number of subjects available for experimen-
tation; however, this scenario is further compounded by
hindrance in observing the effects of increasing doses of
ethanol in healthy volunteers. In light of these complica-
tions, animal models have permitted the experimental
control necessary in the investigation of the long-term
effects of ethanol and the dose-response effect on sleep
architecture.
In conclusion, this study presents data concerning the
effects of ethanol on sleep and suggests that the cholin-
ergic system interacts with ethanol and sleep in rodents.
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